You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
強生(JNJ.US)T細胞療法在淋巴瘤臨牀研究獲良好初步結果
阿思達克 06-14 00:27
強生(JNJ.US)表示,其CAR-T細胞療法JNJ-4496在首批臨牀研究中,對復發或難治性大型B細胞淋巴瘤(LBCL)展現出正面療效。公司指出,接受建議二期劑量的患者中,完全緩解率達75%至80%。 該療法針對CD19與CD20兩種常見於惡性B細胞表面的抗原,有望克服傳統治療的抗藥性問題。數據亦顯示療法安全性良好,未見三級或四級的細胞激素釋放症候羣(CRS)個案,僅出現兩宗神經毒性事件,其中一宗爲三級,與中樞神經系統淋巴瘤有關。 常見副作用包括嗜中性白血球低下,整體而言有84%患者出現三級或四級治療相關不良反應,最常見是白血球減少。強生認爲,該項治療爲侵略性淋巴瘤患者帶來新希望。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account